2014 News

11.25.2014 Press Release

Santen Launches TAPCOM Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension

11.18.2014 Press Release

Intravitreal VEGF Inhibitor "EYLEA" Obtains Additional Indication of Diabetic Macular Edema (DME), its Fourth Indication

11.12.2014 Press Release

Santen and Singapore Eye Research Institute (SERI) Announce a Collaboration to Develop New Ophthalmic Therapeutics

11.07.2014 Information

Meeting video on Financial Results of the 2nd Quarter of FY2014

11.05.2014 Press Release

Santen Announces Financial Result for the Second Quarter ended September 30, 2014

10.31.2014 Press Release

Santen Receives Financing from the Development Bank of Japan based on "DBJ Environmental Rating"

10.08.2014 Information

Santen to release Annual Report 2014

10.02.2014 Press Release

Santen Announces Closing of Asset Purchase Agreement with Respect to Acquisition of Ophthalmology Assets from Merck

09.25.2014 Press Release

Increase of Capital for a Consolidated Subsidiary in Europe

09.22.2014 Press Release

Intravitreal VEGF Inhibitor "EYLEA" Obtains Additional Indication of Myopic Choroidal Neovascularization (mCNV)

09.09.2014 Press Release

Eyestrain Common Issue Caused by Contact Lenses!? Santen Launches Soft Santear Hitomi Stretch, an Eye Drop for Use with Soft Contact Lenses to Reduce Eyestrain by Relaxing Ciliary Muscle Stiffness Which Can Be a Cause of Eyestrain

09.01.2014 Press Release

Notice on Details of the Rights to Subscribe for New Shares (Stock Options as Stock-Linked Remuneration)

08.15.2014 Press Release

Santen Files for Manufacturing/Marketing Approval of its Glaucoma and Ocular Hypertension Therapeutic, COSOPT Mini Combination Ophthalmic Solution

08.08.2014 Information

Meeting video on Financial Results of the 1st Quarter of FY2014 and Medium-term management plan for FY2014-2017

08.05.2014 Press Release

Santen Announces Financial Result for the First Quarter ended June 30, 2014

08.05.2014 Press Release

Santen to Grant Rights to Subscribe for New Shares as Stock Options as Stock-Linked Remuneration

08.05.2014 Press Release

Medium-Term Management Plan FY2014-2017

08.05.2014 Information

Posted new contents "Carrying Ophthalmologists Aspirations"

07.29.2014 Press Release

Changes in Significant Shareholders

07.02.2014 Press Release

Santen Announces Closing of Asset Purchase Agreement with Respect to Acquisition of Ophthalmology Assets from Merck

05.20.2014 Information

Posted meeting video on the Financial Result of FY2013

05.13.2014 Press Release

Santen Announces Financial Results for the Year ended March 31, 2014

05.13.2014 Press Release

Notice of the Nominations for the Member of the Board

05.13.2014 Press Release

Santen Announces the Signing of Agreement between Merck for the Purchase of Assets in Ophthalmology

04.07.2014 Press Release

Santen Phase III Study Meets Primary Endpoint for The treatment of Non-Infectious Posterior Segment Uveitis (NI-PSU)

04.04.2014 Press Release

Santen Partners with Akorn, Inc. subsidiary Oak Pharmaceuticals for Marketing of Tafluprost, the Treatment of Glaucoma and Ocular Hypertension in the U.S.

03.28.2014 Press Release

The Osaka Study: An epidemiological survey showing that dry eye disease lowers work productivity, affects quality of life and correlates with metabolic syndrome

03.10.2014 Press Release

Notice of the appointment of Corporate Officers

03.04.2014 Press Release

Santen and TRACON Announce Agreement for the Development and Commercialization of TRC105 in Ophthalmology

02.20.2014 Press Release

Changes in Significant Shareholders

02.04.2014 Press Release

Revision of consolidated earnings forecasts for FY 2013

02.04.2014 Press Release

Santen Announces Financial Result for the Third Quarter ended December 31, 2013

02.04.2014 Press Release

Santen Pharmaceutical Voluntarily Adopts International Financial Reporting Standards (IFRS)